Casdatifan - Arcus Biosciences
Alternative Names: AB-521; HIF-2a inhibitor - Arcus BiosciencesLatest Information Update: 29 Jun 2026
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; AstraZeneca
- Class Alcohols; Antineoplastics; Fluorinated hydrocarbons; Fluorobenzenes; Indenes; Nitriles; Organic sulfur compounds; Small molecules; Sulfides; Tetrahydronaphthalenes
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Renal cell carcinoma
- Phase I Cancer; Solid tumours
- No development reported Liver cancer
Most Recent Events
- 12 Jun 2026 Arcus Biosciences plans a phase I trial for Healthy volunteers in USA in June 2026 (PO) (NCT07641881)
- 29 May 2026 Arcus Biosciences initiates phase I trial (In volunteers) in the USA (PO, Tablet) (NCT07641881)
- 10 Mar 2026 Chemical structure information added.